6/24
08:00 am
lxrx
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
6/21
08:00 am
lxrx
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
Medium
Report
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
6/19
08:38 am
lxrx
Data From Lexicon's RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association [Yahoo! Finance]
Low
Report
Data From Lexicon's RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association [Yahoo! Finance]
6/19
08:00 am
lxrx
Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association
Low
Report
Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association
6/18
08:15 am
lxrx
Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology [Yahoo! Finance]
Low
Report
Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology [Yahoo! Finance]
6/18
08:00 am
lxrx
Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology
Low
Report
Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology
6/17
07:38 am
lxrx
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $10.00 price target on the stock.
High
Report
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $10.00 price target on the stock.
6/14
08:13 am
lxrx
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association [Yahoo! Finance]
Low
Report
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association [Yahoo! Finance]
6/14
08:00 am
lxrx
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association
Low
Report
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association
6/11
08:38 am
lxrx
Lexicon Pharmaceuticals (NASDAQ:LXRX) adds US$51m to market cap in the past 7 days, though investors from five years ago are still down 69% [Yahoo! Finance]
Low
Report
Lexicon Pharmaceuticals (NASDAQ:LXRX) adds US$51m to market cap in the past 7 days, though investors from five years ago are still down 69% [Yahoo! Finance]
6/10
05:50 pm
lxrx
Postherpetic Neuralgia Market to Accelerate Significantly at a CAGR of 14% by 2034 | DelveInsight [Yahoo! Finance]
Low
Report
Postherpetic Neuralgia Market to Accelerate Significantly at a CAGR of 14% by 2034 | DelveInsight [Yahoo! Finance]
6/6
10:02 pm
lxrx
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was upgraded by analysts at StockNews.com to a "sell" rating.
Low
Report
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was upgraded by analysts at StockNews.com to a "sell" rating.
5/29
08:34 am
lxrx
Lexicon Pharmaceuticals Selects Medidata to Help Advance First Non-Opioid Drug for Neuropathic Pain in Over Two Decades [Yahoo! Finance]
Low
Report
Lexicon Pharmaceuticals Selects Medidata to Help Advance First Non-Opioid Drug for Neuropathic Pain in Over Two Decades [Yahoo! Finance]
5/29
07:30 am
lxrx
Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024
Low
Report
Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024
5/14
07:08 am
lxrx
New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction [Yahoo! Finance]
Low
Report
New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction [Yahoo! Finance]
5/14
07:00 am
lxrx
New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction
Medium
Report
New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction
5/9
07:30 am
lxrx
Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024
Medium
Report
Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024
5/6
10:12 am
lxrx
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/3
08:53 am
lxrx
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Medium
Report
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
5/2
07:52 pm
lxrx
Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue Estimates [Yahoo! Finance]
Medium
Report
Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue Estimates [Yahoo! Finance]
5/2
04:13 pm
lxrx
Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
5/2
04:05 pm
lxrx
Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Low
Report
Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
5/2
07:27 am
lxrx
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
Low
Report
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
5/1
02:05 am
lxrx
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was upgraded by analysts at StockNews.com to a "sell" rating.
Medium
Report
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was upgraded by analysts at StockNews.com to a "sell" rating.
4/30
07:15 am
lxrx
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $5.00 price target on the stock.
Low
Report
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $5.00 price target on the stock.